Association of Time-to-Intravenous Furosemide with Mortality in Acute Heart Failure: Data from REPORT-HF
Key result
Longer time to IV furosemide is linked to increased 30-day mortality, especially in high-risk patients.
- P=0.016
- n=15,078
Why the study?
Delaying intravenous furosemide in acute heart failure has been postulated to increase mortality, but prior reports have been inconclusive.
Does longer time-to-intravenous furosemide increase mortality in patients with acute heart failure?
Population
15 078 acute heart failure patients from seven world regions in the REPORT-HF registry
Comparison
Time-to-diuretics within the first 24 h
Design
International registry
Follow-up
30-day post-discharge
Authors
Discussion
Loading...
Member takes
Implication
Longer time-to-diuretics was associated with higher 30-day mortality in high-risk patients; leaves open whether earlier treatment improves acute HF outcomes.
Study Design
Type
Observational (n=15,078)
Multicenter
Yes
Structured PICO
Does longer time-to-intravenous furosemide increase mortality in patients with acute heart failure?
P
Population
15,078 patients with acute heart failure from the international REPORT-HF registry, assessed for the association of time-to-diuretics with mortality over 30 days.
E
Exposure
Longer time-to-intravenous furosemide (time-to-diuretics) within the first 24 hours of hospital arrival
C
Comparator
Shorter time-to-intravenous furosemide
O
Outcome
In-hospital mortality and 30-day post-discharge mortalityhard clinical
Main Result
p-value: p=0.016
Delayed administration of intravenous furosemide in acute heart failure is associated with increased 30-day mortality, particularly in high-risk patients, supporting prompt diuretic therapy.
Cite This Study
Ouwerkerk et al. (2022) conducted an observational in Acute heart failure (n=15,078). Time-to-intravenous furosemide vs. Shorter time-to-diuretics was evaluated on In-hospital and 30-day post-discharge mortality (p=0.016). Longer time-to-intravenous furosemide was associated with increased 30-day mortality (p=0.016), particularly in high-risk patients, but not with in-hospital mortality.